Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE® U.S. net product revenues, including…
Robust plan benefits powered member growth, mainly driven by switchers from other plansCompany will focus on balancing profitability with strategic…
Fourth Quarter 2024 worldwide revenue of ~$48.8 to $49.0 million representing growth of ~26%Achieved adjusted EBITDA profitability in the fourth…
Entering 2025 having demonstrated rapid translation of genetic insights to positive clinical data; advancing clinically validated and multi-modal pipeline with…
More patients treated with ZTlido® saw either a decrease or discontinuation of opioid use compared with those treated with the…
ATTENS (ADHD trial of external trigeminal nerve stimulation) Project, led by Professor Katya Rubia at the Institute of Psychiatry, Psychology…
The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An Express License provides fast,…
Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea preparing icovamenib for late-stage clinical development2025 corporate…
AAMI Document Clarifies Repair RequirementsArlington, VA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Alternate equipment management (AEM) plans for medical devices…
Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell CarcinomaMarlborough, Massachusetts--(Newsfile Corp. - January 13, 2025) - Phio…